Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Leukemia and Lymphoma

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v78.10.2759.bloodjournal78102759PMID 8374516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia.

  1992cited by this paper
• Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation.

  1992cited by this paper
• Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.

  1992cited by this paper
• Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.

  1992cited by this paper
• Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

  1991cited by this paper
• All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.

  1991cited by this paper
• Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.

  1991cited by this paper
• Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.

  1991cited by this paper
• Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

  1991cited by this paper
• bcr/abl mRNA DETECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA

  1991cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.

  1990cited by this paper
• Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers

  1990cited by this paper
• Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain.

  1989cited by this paper
• Minimal residual leukaemia in chronic myeloid leukaemia patients after T-cell depleted bone-marrow transplantation.

  1989cited by this paper
• Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia.

  1989cited by this paper
• Indications for marrow transplantation in chronic myelogenous leukemia.

  1989cited by this paper
• Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation.

  1989cited by this paper
• Detection of 14;18 chromosomal translocation in paraffin-embedded lymphoma tissue.

  1989cited by this paper
• Differential effects of tumor promoters on P210bcr-abl expression.

  1989cited by this paper
• Polymerase chain reaction for detection of residual leukaemia.

  1989cited by this paper
• Avoiding false positives with PCR

  1989cited by this paper
• Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

  1988cited by this paper
• The molecular genetics of Philadelphia chromosome-positive leukemias.

  1988cited by this paper
• Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.

  1988cited by this paper
• HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration.

  1988cited by this paper
• Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase.

  1988cited by this paper
• The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia

  1987cited by this paper
• T lymphocytes lack rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myelocytic leukemia.

  1987cited by this paper
• Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease.

  1987cited by this paper
• Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.

  1987cited by this paper
• Philadelphia‐positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia

  1986cited by this paper
• Marrow transplantation for the treatment of chronic myelogenous leukemia.

  1986cited by this paper
• Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

  1986cited by this paper
• Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

  1985cited by this paper
• Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products

  1985cited by this paper
• The emerging genetics of acute lymphoblastic leukemia: clinical and biologic implications.

  1985cited by this paper
• Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

  1985cited by this paper
• Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.

  1985cited by this paper
• Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma.

  1984cited by this paper
• Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

  1984cited by this paper
• An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

  1984cited by this paper
• Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

  1983cited by this paper
• Involvement of the B-lymphoid system in chronic myelogenous leukaemia

  1980cited by this paper
• Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

  1979cited by this paper
• Origin of chronic myelocytic leukemia in a precursor of pre-B lymphocytes.

  1979cited by this paper
• Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

  1977cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of Ph1 chromosome.

  1970cited by this paper

• Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

  2000cites this paper
• Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.

  1999cites this paper
• Graft‐vs.‐malignancy with allogeneic blood stem cell transplantation: A potential primary treatment modality

  1999cites this paper
• Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice.

  1999cites this paper
• Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.

  1998cites this paper
• Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study.

  1996cites this paper
• Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.

  1995cites this paper
• Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.

  1995cites this paper
• Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.

  1994cites this paper
• E2A/HLF fusion cDNAs and the use of RT-PCR for the detection of minimal residual disease in t(17;19)(q22;p13) acute lymphoblastic leukemia.

  1994cites this paper
• Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.

  1994cites this paper
• Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.

  1991cites this paper